Parallel Consultations An overview of the procedure Presented by - - PowerPoint PPT Presentation

▶
parallel consultations
SMART_READER_LITE
LIVE PREVIEW

Parallel Consultations An overview of the procedure Presented by - - PowerPoint PPT Presentation

Nov 08, 2022 257 likes •491 views

Parallel Consultations An overview of the procedure Presented by Jane Moseley on 17 November 2017 Senior Scientific Officer Scientific Advice Office An agency of the European Union Outline Parallel advice with HTAs Rationale and Impact

slide-1
SLIDE 1

An agency of the European Union

Parallel Consultations

An overview of the procedure

Presented by Jane Moseley on 17 November 2017 Senior Scientific Officer – Scientific Advice Office

slide-2
SLIDE 2

Outline

Parallel advice with HTAs

  • Rationale and Impact of parallel advice
  • European level landscape for advice

New procedure

  • HTA actors, outline of the process and outcomes
  • Experience since launch

Key messages

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 1 17 November 2017

slide-3
SLIDE 3

Background

  • Starting point: Regulators and Health Technology

Assessment (HTA) bodies come together early

  • to discuss the planned development
  • Expectation: Optimised development plan  efficient 

Improve access for patients

  • How best to do this interaction?
  • Recently launched single platform
  • EMA and EUnetHTA as equal partners

2 SME Info Day Multi-stakeholder parallel regulators/HTAs advice 17 November 2017

slide-4
SLIDE 4

Parallel consultations EMA - HTA parallel Scientific Advice SEED EUnetHTA's early dialogue initiative

Why and how we have got here

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 3

As of the 4th of July 2017 this initiative replaces the parallel scientific advice procedure by EMA and HTA bodies which required medicine developers to contact Member States’ HTA bodies individually. Best practice guidance for the parallel regulatory - HTA scientific advice procedure (EMA/502692/2015 ) Guidance for parallel consultation (EMA/410962/2017) Replaced by

17 November 2017

slide-5
SLIDE 5

How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice

British Journal of Clinical Pharmacology. Tafuri et al Volume 82, Issue 4, pages 965-973, 1 JUL 2016 DOI: 10.1111/bcp.13023 http://onlinelibrary.wiley.com/doi/10.1111/bcp.13023/full#bcp13023-fig-0003

17 November 2017 4

slide-6
SLIDE 6

EU-level Advice Landscape

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 17 November 2017

Regulator advice

  • CHMP advice
  • HTA observers

as option subject to EMA confidentiality undertaking Parallel consultation

  • Regulators and

HTAS

  • CHMP advice
  • HTAS
  • PCC
  • PCI

HTA advice

  • Consolidated
  • EMA as
  • bservers

subject to EUnetHTA confidentiality undertaking

Eligibility criteria, Fees and Legal Basis are the same for EMA

5

slide-7
SLIDE 7

New procedure EMA and EUnetHTA

The main benefits of the parallel consultation procedure include:

  • A Streamlined procedure for Applicants;
  • Increased opportunities for mutual understanding and problem-

solving ability between EMA and HTA bodies through a more structured interaction;

  • Improved coordination with, and greater participation of HTA

bodies in parallel consultations through EUnetHTA's Early Dialogue Working Party (EDWP) and the EUnetHTA ED Secretariat.

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 6

This facilitates optimal and robust evidence generation for different stakeholders bringing benefits for patient access and public health. Optimised development plan  Improved access for patients

17 November 2017

slide-8
SLIDE 8

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 7

What is new / different?

17 November 2017

slide-9
SLIDE 9

EUnetHTA Actors

  • Organisation and contact point
  • Acceptability of the Letter of Intent and all project management on the

HTABs side.

  • HAS

EUnetHTA ED Secretariat

  • Is a standing committee established by EUnetHTA to ensure robust

high-quality HTA outputs.

  • All EDWP members will participate in procedures selected for

Consolidated PC.

Early Dialogues Working Party (EDWP)

  • Is constituted for a specific product and the members will fluctuate to a

degree for each Consultation.

The Early Dialogue Committee (EDC)

  • Undertakes scientific coordination on behalf of HTAs.
  • Facilitates discussion between HTABs in advance of meetings.
  • co-chair for the HTABs for the F2F meeting.

EDC Scientific Coordinator

8 17 November 2017

slide-10
SLIDE 10
  • The product should aim to bring added benefit to patients i.e. by:

SELECTION CRITERIA: A new mode of action for the indication AND targeting a life-threatening or chronically debilitating disease AND responding to unmet need (no treatment or only unsatisfactory treatment available).

PC Consolidated PC Individual

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 9

EUnetHTA: EDWP selection criteria

Choice of pathway:

17 November 2017

slide-11
SLIDE 11
  • The preferences of the Applicant (indicated in the Letter of Intent) will be taken

into account, but participation of those HTABs cannot be guaranteed.

Composition of the EDWP as of July 4th 2017: France (HAS), Germany (G-BA), United Kingdom (NICE), Italy (AIFA with alternate RER), Hungary (NIPN), and a shared seat for The Netherlands/ Belgium (ZIN/ RIZIV-INANMI)

EUnetHTA: EDC

Consolidated PC Individual PC

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 10

HTAB C* HTAB B* HTAB A*

HTAB E* HTAB D* HTAB C* HTAB B* HTAB A*

* From EUnetHTA WP5

  • For a specific product and the members will fluctuate to a degree for each

Consultation.

  • Composition (example) of the EDC for:

+

NIPN

AIFA / RER

NICE G-BA HAS ZIN / RIZIV-INANMI

EDWP

17 November 2017

slide-12
SLIDE 12

PC – Consolidated vs Individual

Parallel Consultations Consolidated Individual HTAB recruitment Centrally via EUnetHTA ED Secretariat Mode of participation of HTABs Full EDWP and <=3 more Voluntary HTAB participation Selection criteria Applies Does not apply Outcome A single written report including: consolidated HTA written answers for shared positions, and individual HTA answers to those questions without consensus. Individual HTABs provide HTABs’ written reports

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 11 17 November 2017

slide-13
SLIDE 13

The process – 3 phases

Simultaneous notification Presubmission phase Evaluation phase

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 12

Deadline: Day - 60 Deadline: Day - 30 As scientific advice

17 November 2017

slide-14
SLIDE 14

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 13

Evaluation phase

List of issues

  • EUnetHTA ED

Secretariat and EMA exchange Lists of Issues (LoI) Pre F2F TC

  • To take place in the

week after SAWP 2

  • Identification and

discussion of critical issues during the

  • TC. If possible, try

identifying possible solutions F2F meeting

  • At the EMA

premises, and will have 2 co-chairs.

  • Tripartite session:

EDC, EMA and the Applicant.

  • The meeting

duration will depend on the range of issues to be discussed and advice format 3-4 hours

17 November 2017

slide-15
SLIDE 15

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 14

Advice / outcome

  • Final outcome letters are exchanged between EMA and

EUnetHTA ED Secretariat.

Parallel Consultations EMA EUnetHTA Consolidated Individual CHMP final Scientific Advice/Protocol Assistance letter to the Applicant in accordance with the published timelines (i.e. the subsequent CHMP meeting). EUnetHTA ED Secretariat sends final written answers to Applicant at ≈D +75. Individual HTABs written answers to Applicant <=15 working days of the F2F .

17 November 2017

slide-16
SLIDE 16

Experience of new procedure Number of parallel consultations (PC) requests

Total number of PC requests as of 10/11/2017: 11

  • Procedures started: 6
  • Procedures finished: 2

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 15

1 2 3 Aug-17 Sep-17 Oct-17 Nov-17 Jan-18

Start date

Number of requests 17 November 2017

73% 18% 9% Individual Consolidated Pending decision

slide-17
SLIDE 17

Features of requests in new procedure

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 16

  • Mostly oncology indications 6, (dermatology, ophthalmology, metabolic,

connective tissue)

  • Patient representatives involvement in all 6 started procedures
  • SME, Orphan and ATMP appear under-represented.

17 November 2017

4 7.5 1 2 3 4 5 6 7 8 PCI PCC

Median no of participating HTABs

Median no of participating HTABs

slide-18
SLIDE 18

HTABs involvement (2)

17

Total number of HTABs involved in Pc procedures: 11 HTABs coordinators:

  • AEMPS: 1 procedure
  • HAS: 2 procedures
  • NICE: 2 procedures
  • G-BA: 2 procedures

86% 71% 29% 43% 29% 43% 57% 29% 14% 14% 14%

0% 10% 20% 30% 40% 50% 60% 70% 80% 90%

Percentage of involvement of HTABs*

*Numbers related to the 7 requests that have confirmed HTABs participants.

slide-19
SLIDE 19

Summary

Positive collaboration between EMA and EUnetHTA

  • New platform, one gateway for all procedures for advice/dialogue
  • Centralised HTA recruitment,
  • HTA working party for prioritised subset with consolidated HTA advice
  • For all parallel advice/early dialogue procedures - Streamlined

logistics, greater HTA coordination

  • Multi-stakeholder, EMA and EUnetHTA equal partners, working

together, benefits patient access and public health

  • Respect for roles and remits to facilitate optimised evidence

generation for different stakeholders

  • Building on successes of PSA and SEED and Interactive focused

meetings

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 18 17 November 2017

slide-20
SLIDE 20

Key messages

  • Platform for parallel discussion on initial evidence generation for

MAA/reimbursement, and post licensing evidence generation

  • Launched 03 July 2017- Early experience so far but positive
  • More procedures /applications for parallel consultation encouraged -

What are the barriers?

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 19 17 November 2017

slide-21
SLIDE 21

Contact EMA scientificadvice scientificadvice@ema.europa.eu Contact EUnetHTA ED secretariat eunethta-has@has-sante.fr

European Medicines Agency

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom

Telephone +44 (0)20 3660 7149 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

Further information

Follow us on @EMA_News

Thank you for your attention

Acknowledgements Inês Lucas EMA, SAWP and EUnetHTA colleagues

slide-22
SLIDE 22
  • Documents and outcomes are exchanged throughout the

procedure, if the Applicant provides consent in the letter of intent

  • More interaction amongst stakeholders, since the beginning of

the procedure, leading to a more efficient process:

  • Administrative TC
  • Pre F2F TC
  • Closed TC (Day 57)
  • Closed regulators/HTAB interaction during the F2F meeting
  • Follow-up procedures
  • Procedures ongoing

SME Info Day Multi-stakeholder parallel regulators/HTAs advice 21

Additional information

17 November 2017